Li Y, Wang X, Chen J, Li Z, Yang P, Qin L
Front Pharmacol. 2021; 11:584425.
PMID: 33584262
PMC: 7873645.
DOI: 10.3389/fphar.2020.584425.
Irwin J, Terrault N
Gastroenterol Hepatol (N Y). 2012; 4(1):65-7.
PMID: 22798739
PMC: 3394472.
Myint A, Schwarz M, Steinbusch H, Leonard B
Metab Brain Dis. 2008; 24(1):55-68.
PMID: 19067144
DOI: 10.1007/s11011-008-9114-5.
Majer M, Welberg L, Capuron L, Pagnoni G, Raison C, Miller A
Brain Behav Immun. 2008; 22(6):870-80.
PMID: 18258414
PMC: 2497339.
DOI: 10.1016/j.bbi.2007.12.009.
Valentine A, Meyers C
Curr Psychiatry Rep. 2005; 7(5):391-5.
PMID: 16216160
DOI: 10.1007/s11920-005-0042-3.
Neuropsychiatric adverse effects of interferon-alpha: recognition and management.
Raison C, Demetrashvili M, Capuron L, Miller A
CNS Drugs. 2005; 19(2):105-23.
PMID: 15697325
PMC: 1255968.
DOI: 10.2165/00023210-200519020-00002.
Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.
Makino M, Kitano Y, Komiyama C, Hirohashi M, Takasuna K
Br J Pharmacol. 2000; 130(6):1269-74.
PMID: 10903965
PMC: 1572192.
DOI: 10.1038/sj.bjp.0703432.
Acute third cranial nerve ophthalmoplegia: possible pathogenesis from alpha-II-interferon treatment.
Pacifici L, Passarelli F, Papa G, Cannone L, Rossini P
Ital J Neurol Sci. 1993; 14(7):579-80.
PMID: 8282531
DOI: 10.1007/BF02339218.
Interferon-alpha in malignant and viral diseases. A review.
Dorr R
Drugs. 1993; 45(2):177-211.
PMID: 7681371
DOI: 10.2165/00003495-199345020-00003.
Clinical toxicity of the interferons.
Vial T, Descotes J
Drug Saf. 1994; 10(2):115-50.
PMID: 7516663
DOI: 10.2165/00002018-199410020-00003.
Neurological effects of recombinant human interferon.
Br Med J (Clin Res Ed). 1983; 286(6370):1054-5.
PMID: 6403186
PMC: 1547529.
DOI: 10.1136/bmj.286.6370.1054-e.
Interferons, a group of multiple lymphokines.
Kirchner H
Springer Semin Immunopathol. 1984; 7(4):347-74.
PMID: 6084313
DOI: 10.1007/BF00201966.
Interferon-beta in patients with low-grade astrocytomas--a phase I study.
Bogdahn U, Fleischer B, Hilfenhaus J, Rothig H, Krauseneck P, MERTENS H
J Neurooncol. 1985; 3(2):125-30.
PMID: 4031971
DOI: 10.1007/BF02228888.
Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial.
PADMANABHAN N, Balkwill F, Bodmer J, Rubens R
Br J Cancer. 1985; 51(1):55-60.
PMID: 3917678
PMC: 1976812.
DOI: 10.1038/bjc.1985.8.
A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion.
Smith D, Wagstaff J, Thatcher N, Scarffe H
Cancer Chemother Pharmacol. 1987; 20(4):327-31.
PMID: 3690806
DOI: 10.1007/BF00262586.
Two cases of influenza B encephalitis.
Hawkins S, Lyttle J, Connolly J
J Neurol Neurosurg Psychiatry. 1987; 50(9):1236-7.
PMID: 3668577
PMC: 1032366.
DOI: 10.1136/jnnp.50.9.1236.
Preclinical safety testing of species-specific proteins produced with recombinant DNA-techniques. An attempt to transfer current experience into future testing strategies.
Teelmann K, Hohbach C, Lehmann H
Arch Toxicol. 1986; 59(4):195-200.
PMID: 3548648
DOI: 10.1007/BF00290537.
Human leukocyte alpha interferon-induced transient neurotoxicity in children.
Katz J, Mahoney D, Steuber C, Fernbach D
Invest New Drugs. 1988; 6(2):115-20.
PMID: 3170131
DOI: 10.1007/BF00195369.
A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.
Sriskandan K, Garner P, Watkinson J, Pettingale K, BRINKLEY D, Calman F
Cancer Chemother Pharmacol. 1986; 18(1):63-8.
PMID: 3093108
DOI: 10.1007/BF00253067.
Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.
Yung W, Steck P, Kelleher P, Moser R, Rosenblum M
J Neurooncol. 1987; 5(4):323-30.
PMID: 2964515
DOI: 10.1007/BF00148389.
